Literature DB >> 17260105

Body composition, insulin, and leptin levels in patients with ankylosing spondylitis.

Ismail Sari1, Tevfik Demir, Leyla Didem Kozaci, Servet Akar, Tulay Kavak, Merih Birlik, Fatos Onen, Nurullah Akkoc.   

Abstract

The aim of this study was to compare the effect of chronic inflammation on insulin resistance, serum leptin levels, and body composition (BC) in patients with ankylosing spondylitis (AS) and healthy controls. Twenty-eight AS patients and 17 healthy controls were included in this study. Subjects with hypertension, diabetes, hyperlipidemia, and obesity were excluded. Acute phase reactants and serum levels of glucose, insulin, lipids, and leptin were studied. BC was determined anthropometrically and by foot-to-foot body fat analyzer (BIA, bioelectrical impedance analysis). Quantitative insulin-sensitivity check index, homeostasis model assessment for insulin resistance, and McAuley indices were calculated. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index and the Bath Ankylosing Spondylitis Disease Activity Index. Age, sex distribution, smoking status, serum lipids, insulin concentrations, and insulin resistance indices were comparable between AS patients and controls (p > 0.05). However, acute phase reactants were significantly higher and leptin levels were significantly lower in the AS patients than in controls (p < 0.05). Fat percent assessed by both BIA and anthropometrical methods was lower in the male and female AS patients than in controls, and this reduced fat level reached statistical significance for men (p < 0.05). There were significant correlations between percent body fat, body mass index, leptin, age, and BASMI (p < 0.05; r = 0.6, 0.75, 0.35, -0.41, respectively). On the other hand, body fat percent, waist-to-hip ratio, C-reactive protein, and BASMI were significantly correlated with serum leptin levels (p < 0.05; r = 0.75, -0.42, -0.52, -0.47, respectively). Chronic inflammatory condition in AS may be responsible for the reduced body fat content and lower circulating leptin concentrations. Insulin levels and insulin resistance indices seem similar in patients and controls in the absence of classic vascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260105     DOI: 10.1007/s10067-006-0509-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  36 in total

1.  Immunoreactive insulin levels in ankylosing spondylitis.

Authors:  F J Jiménez-Balderas; J L Solís; G Mintz
Journal:  Arch Invest Med (Mex)       Date:  1991 Apr-Jun

2.  Attenuated insulin response and normal insulin sensitivity in lean patients with ankylosing spondylitis.

Authors:  A Penesova; J Rovensky; M Zlnay; L Dedik; Z Radikova; J Koska; M Vigas; R Imrich
Journal:  Int J Clin Pharmacol Res       Date:  2005

Review 3.  Human body composition: in vivo methods.

Authors:  K J Ellis
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

Review 4.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.

Authors:  Mike J Peters; Irene E van der Horst-Bruinsma; Ben A Dijkmans; Michael T Nurmohamed
Journal:  Semin Arthritis Rheum       Date:  2004-12       Impact factor: 5.532

Review 5.  Leptin in immunology.

Authors:  Giuseppe Matarese; Stergios Moschos; Christos S Mantzoros
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

6.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

7.  Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones.

Authors:  K L Svenson; G Lundqvist; L Wide; R Hällgren
Journal:  Metabolism       Date:  1987-10       Impact factor: 8.694

8.  Insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis.

Authors:  E Toussirot; N U Nguyen; G Dumoulin; J Regnard; D Wendling
Journal:  Br J Rheumatol       Date:  1998-11

9.  Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor.

Authors:  R Roubenoff; R A Roubenoff; L M Ward; S M Holland; D B Hellmann
Journal:  J Rheumatol       Date:  1992-10       Impact factor: 4.666

10.  Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance.

Authors:  K L Svenson; T Pollare; H Lithell; R Hällgren
Journal:  Metabolism       Date:  1988-02       Impact factor: 8.694

View more
  23 in total

Review 1.  Roles of leptin in bone metabolism and bone diseases.

Authors:  Xu Xu Chen; Tianfu Yang
Journal:  J Bone Miner Metab       Date:  2015-03-18       Impact factor: 2.626

2.  Down-regulation of adiponectin in patients with familial Mediterranean fever during attack-free period.

Authors:  Vedat Gerdan; Ismail Sari; Didem Kozacı; Fatos Önen; Feride Yüksel; Ozgül Soysal; Dilek Solmaz; Necati Günay; Nurullah Akkoc; Servet Akar
Journal:  Rheumatol Int       Date:  2011-08-30       Impact factor: 2.631

3.  Impaired hypothalamo-pituitary-adrenal axis in patients with ankylosing spondylitis.

Authors:  L Kebapcilar; O Bilgir; A Alacacioglu; Y Yildiz; A Taylan; R Gunaydin; A Yuksel; B Karaca; I Sari
Journal:  J Endocrinol Invest       Date:  2009-07-20       Impact factor: 4.256

4.  Relationship between serum leptin level and disease activity in patients with systemic sclerosis.

Authors:  Mahmut Budulgan; Banu Dilek; Şevin Buluttekin Dağ; Ibrahim Batmaz; İsmail Yıldız; Mustafa Akif Sarıyıldız; Remzi Çevik; Kemal Nas
Journal:  Clin Rheumatol       Date:  2013-12-27       Impact factor: 2.980

5.  Leptin as an open secret in the physiopathology of rheumatic diseases.

Authors:  Mónica Vázquez-Del Mercado; Erika A Martínez-García
Journal:  Clin Rheumatol       Date:  2020-01-11       Impact factor: 2.980

Review 6.  Leptin: an unappreciated key player in SLE.

Authors:  Qihang Yuan; Haifeng Chen; Xia Li; Jing Wei
Journal:  Clin Rheumatol       Date:  2019-11-09       Impact factor: 2.980

7.  Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.

Authors:  Carrie Wagner; Sudha Visvanathan; Jürgen Braun; Désirée van der Heijde; Atul Deodhar; Benjamin Hsu; Michael Mack; Michael Elashoff; Robert D Inman
Journal:  Ann Rheum Dis       Date:  2011-10-28       Impact factor: 19.103

Review 8.  Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases.

Authors:  Morena Scotece; Javier Conde; Rodolfo Gómez; Verónica López; Jesús Pino; Antonio González; Francisca Lago; Juan J Gómez-Reino; Oreste Gualillo
Journal:  Mediators Inflamm       Date:  2012-07-15       Impact factor: 4.711

Review 9.  The role of adipokines in connective tissue diseases.

Authors:  Robert Krysiak; Gabriela Handzlik-Orlik; Boguslaw Okopien
Journal:  Eur J Nutr       Date:  2012-05-15       Impact factor: 5.614

Review 10.  Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response.

Authors:  Claire I Daïen; Jérémie Sellam
Journal:  RMD Open       Date:  2015-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.